Corticosteroid Lumbar Epidural Analgesia for Radiculopathy

NCT ID: NCT03372161

Last Updated: 2022-09-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

401 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-08

Study Completion Date

2022-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a research study of SP-102, an experimental medication designed to relieve pain in patients with a specific type of leg pain. The medication is given once by your healthcare professional, with a possibility of a second injection as early as about 1 month after the first treatment.

The purpose of the study is to measure how well a single injection of the experimental medication, SP-102, relieves pain. The study will also investigate the side effects of SP-102.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbosacral Radicular Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SP-102

SP-102

Group Type EXPERIMENTAL

SP-102

Intervention Type DRUG

injection

Placebo

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SP-102

injection

Intervention Type DRUG

Placebo

injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able and willing to read, write, and understand the English language and provide English language written informed consent prior to beginning any study procedures.
* Age 18 to 70 years (inclusive) at the Screening Visit.
* A diagnosis of lumbosacral radicular pain (sciatica).
* Agrees to follow study-specific medication requirements.
* If sexually active and a female of child-bearing potential or a male capable of bearing a child, agrees to use an effective method of birth control during the study.
* Has reviewed all study specific materials and has, in the opinion of the Investigator, the abilities to understand and appropriately complete all study procedures.

Exclusion Criteria

* Has radiologic evidence of a condition that would compromise study outcomes.
* Has ever had lumbosacral back surgery or plans to undergo spine surgical intervention while in the study.
* Has been diagnosed with insulin dependent diabetes mellitus.
* Presence of any other disorder, condition or circumstance (including secondary gain) that, in the opinion of the Investigator, has the potential to prevent study completion and/or to have a confounding effect on outcome assessments.
* Use of any investigational drug and/or device within 30 days, or is scheduled to receive an investigational drug other than blinded study drug during this study.
* Has a body mass index ≥40 kg/m2.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Worldwide Clinical Trials

OTHER

Sponsor Role collaborator

Semnur Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role collaborator

Scilex Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dmitri Lissin, MD

Role: STUDY_DIRECTOR

Scilex Pharmaceuticals, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Semnur Research Site 75

Mobile, Alabama, United States

Site Status

Semnur Research Site 52

Phoenix, Arizona, United States

Site Status

Semnur Research Site 58

Tempe, Arizona, United States

Site Status

Semnur Research Site 18

La Jolla, California, United States

Site Status

Semnur Research Site 47

Laguna Woods, California, United States

Site Status

Semnur Research Site 70

Los Gatos, California, United States

Site Status

Semnur Research Site 56

Fernandina Beach, Florida, United States

Site Status

Semnur Research Site 81

Jacksonville, Florida, United States

Site Status

Semnur Research Site 49

St. Petersburg, Florida, United States

Site Status

Semnur Research Site 13

Tampa, Florida, United States

Site Status

Semnur Research Site 61

Tampa, Florida, United States

Site Status

Semnur Research Site 53

Winter Park, Florida, United States

Site Status

Semnur Research Site 28

Marietta, Georgia, United States

Site Status

Semnur Research Site 64

Marietta, Georgia, United States

Site Status

Semnur Research Site 10

Newnan, Georgia, United States

Site Status

Semnur Research Site 38

Boise, Idaho, United States

Site Status

Semnur Research Site 40

Bloomington, Illinois, United States

Site Status

Semnur Research Site 63

Chicago, Illinois, United States

Site Status

Semnur Research Site 12

Chicago, Illinois, United States

Site Status

Semnur Research Site 19

Chicago, Illinois, United States

Site Status

Semnur Reseach Site 62

Overland Park, Kansas, United States

Site Status

Semnur Research Site 51

Burlington, Massachusetts, United States

Site Status

Semnur Research Site 65

Omaha, Nebraska, United States

Site Status

Semnur Research Site 60

Las Vegas, Nevada, United States

Site Status

Semnur Research Site 30

Shrewsbury, New Jersey, United States

Site Status

Semnur Research Site 11

Durham, North Carolina, United States

Site Status

Semnur Research Site 20

Winston-Salem, North Carolina, United States

Site Status

Semnur Research Site 46

Cleveland, Ohio, United States

Site Status

Semnur Research Site 43

Cuyahoga Falls, Ohio, United States

Site Status

Semnur Research Site 36

Oklahoma City, Oklahoma, United States

Site Status

Semnur Research Site 48

Charleston, South Carolina, United States

Site Status

Semnur Research Site 77

Greenville, South Carolina, United States

Site Status

Semnur Research Site 15

Houston, Texas, United States

Site Status

Semnur Research Site 54

Plano, Texas, United States

Site Status

Semnur Research Site 35

Tyler, Texas, United States

Site Status

Semnur Research Site 59

Draper, Utah, United States

Site Status

Semnur Research Site 42

Greenfield, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Miller A, Candido KD, Knezevic NN, Rivera J, Lunseth P, Levinson DJ, Formoso F, Solanki D, Tavel E, Krull A, Radnovich R, Burkhead D, Souza D, Helm S, Katz N, Dworkin RH, Cohen SP, Rathmell JP, Buvanendran A, Levin J, Stannard E, Ambrose C, Jaros M, Vought K, Lissin D. A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain. Pain. 2024 Dec 1;165(12):2762-2773. doi: 10.1097/j.pain.0000000000003287. Epub 2024 Jun 14.

Reference Type DERIVED
PMID: 38875121 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SP-102-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

First-In-Human PainCart Study for STR-324
NCT03430232 COMPLETED PHASE1